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Abstract: Histone acetylation and deacetylation play important roles in the regulation of gene 
transcription and in the modulation of chromatin structure. The levels of histone acetylation are 
determined by the activities of histone acetyltransferases and histone deacetylases (HDACs). 
HDACs are associated with a number of oncogenes and tumor suppressor genes and can be 
aberrantly expressed and/or inappropriately activated in cancer cells. HDAC inhibitors have 
therefore recently emerged as a novel treatment modality against malignancies. They regulate 
gene expression by enhancing the acetylation of not only histones but also nonhistone proteins, 
including transcription factors, transcription regulators, signal transduction mediators, and DNA 
repair enzymes, and they inhibit cancer growth. Vorinostat (suberoylanilide hydroxamic acid) is 
one of the most potent HDAC inhibitors, and was approved in Japan in 2011 for the treatment 
of cutaneous T-cell lymphoma. Numerous clinical trials have shown it to be effective against 
cutaneous T-cell lymphoma but less so against other types of cancer. Because vorinostat can 
overcome resistance to or enhance the efficacy of other anticancer agents, such as 5-fluorouracil, 
carboplatin, paclitaxel, bortezomib, and tamoxifen, combination therapies using vorinostat and 
these agents have been investigated. This review introduces the background and mechanism of 
action of vorinostat and describes the results of clinical trials using vorinostat, both as a single 
agent and in combination with other anticancer agents, against cutaneous T-cell lymphoma 
and other malignancies.
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Introduction
Treatment modalities for advanced malignancies are limited, and new approaches 
are urgently needed. The acetylation and deacetylation of histones play important 
roles in the regulation of gene transcription and in the modulation of chromatin 
structure.1,2 In general, increased histone acetylation is associated with increased 
transcriptional   activity, whereas decreased acetylation is associated with repression 
of gene   expression.3 The levels of histone acetylation reflect the balance between the 
activities of histone acetyltransferases and histone deacetylases (HDACs),3 and 18 
HDAC enzymes have been identified in humans. HDACs 1, 2, 3, and 8 are class I 
HDACs, and HDACs 4, 5, 6, 7, 9, and 10 are class II HDACs.4 Unlike the class I and 
class II HDACs, class III HDACs (sirtuins) are nicotinamide adenine dinucleotide-
dependent protein deacetylases.5 Class IV consists of HDAC 11, which has residues 
in the catalytic core region that are also found in class I and II HDACs.6   Deacetylation 
of histones tightens their interaction with DNA, resulting in a closed chromatin struc-
ture and inhibiting gene transcription.7 Furthermore, HDACs also deacetylate many 
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proteins other than histones, thereby increasing or   decreasing 
the function or stability of those proteins.8 Among the non-
histone proteins targeted by HDACs are transcription fac-
tors, transcription regulators, signal transduction mediators, 
DNA repair enzymes, nuclear import regulators, chaperone 
proteins, structural proteins, inflammation mediators, and 
viral proteins.9 HDACs are thus associated with a number 
of cellular oncogenes and tumor suppressor genes, leading 
to aberrant recruitment of HDAC activity, which results 
in changes in gene expression.10,11 HDACs can be aber-
rantly expressed and/or inappropriately activated in cancer: 
HDAC1 is overexpressed in prostate, gastric, colon, and 
breast cancers,12–15 and HDAC2 is overexpressed in colorec-
tal,   cervical, and gastric cancers.16–18 Compounds targeting 
HDACs have therefore generated a great deal of interest as 
anticancer drugs.19 Vorinostat (suberoylanilide hydroxamic 
acid), first reported by Richon et al,20 is one of the most potent 
HDAC inhibitors and is the first approved by the US Food 
and Drug Administration.21
This review introduces the background and mechanism 
of action of vorinostat and describes the results of clinical 
trials using vorinostat, both as a single agent and in combi-
nation with other anticancer agents, against cutaneous T-cell 
lymphoma (CTCL) and other malignancies.
Development of vorinostat
The development of vorinostat started with the discovery of 
hexamethylene bisacetamide (HMBA),22 a hybrid polar com-
pound that induces terminal differentiation of transformed 
cells.23 It was thought to modulate the membrane surface 
potential of transformed cells and thereby perhaps activate 
a signaling pathway,24,25 but its molecular target was not 
identified. HMBA was not well tolerated by patients because 
the high optimal concentration (millimolar level) was associ-
ated with toxic side effects, such as thrombocytopenia.20,26 
Vorinostat is one of the second-generation hybrid polar 
compounds with about 2000-fold greater potency that were 
developed in efforts to overcome these problems.20 Unlike 
HMBA but like trichostatin A, these novel compounds can 
inhibit HDACs.27
HDAC inhibitors
Numerous HDAC inhibitors have been developed and many 
of them have been tested in preclinical and early clinical 
  studies.28 HDAC inhibitors can be classified as hydroxamic 
acids, aliphatic acids, cyclic peptides, or benzamides. 
  Vorinostat is a hydroxamic acid and has structure similar 
to that of trichostatin A, the first natural hydroxamate 
found to inhibit HDACs.29 Panobinostat is also an analog of 
hydroxamic acids and has been investigated in patients with 
refractory hematologic malignancies,30 CTCL,31 Hodgkin 
lymphoma,32 renal cell cancer,33 and castration-resistant pros-
tate cancer.34 Belinostat is another hydroxamic acid-derived 
type of HDAC inhibitor, and its efficacy has been examined 
in clinical trials in patients with advanced hematological 
neoplasia,35 advanced solid tumors,36 recurrent or refractory 
advanced thymic epithelial tumors,37 platinum-resistant epi-
thelial ovarian cancer and micropapillary ovarian tumors,38 
and advanced malignant pleural mesothelioma.39
Phenylbutyrate and valproic acid are aliphatic acid HDAC 
inhibitors,28 but their optimal concentrations are at millimolar 
levels and their inhibitory effects are weak.29 Depsipeptide 
(romidepsin, FK228) is one of the cyclic peptides40 that the 
Food and Drug Administration approved (in November 
2009) for the treatment of CTCL.41 It has also been clini-
cally investigated in patients with other malignancies, such 
as chronic lymphocytic and acute myeloid leukemias,42 
refractory metastatic renal cell cancer,43 lung cancer,44,45 
myelodysplastic syndromes,46 previously treated advanced 
colorectal cancer,47 metastatic castration-resistant prostate 
cancer,48 refractory multiple myeloma,49 and recurrent 
malignant glioma.50 Entinostat (SNDX-275, MS-275) is a 
synthetic benzamide derivative and has been investigated 
in clinical trials in patients with refractory solid tumors and 
lymphoma,51,52 refractory and relapsed acute leukemias,53 
and pretreated metastatic melanoma.54 The effectiveness 
of entinostat is also being investigated in a Phase II trial in 
patients with relapsed or refractory Hodgkin lymphoma.55 
Vorinostat is one of the most potent HDAC inhibitors and 
in October 2006 became the first one approved by the Food 
and Drug Administration for the treatment of advanced 
primary CTCL.21
Molecular effect of vorinostat
Vorinostat inhibits HDACs and induces the accumulation 
of acetylated histones and acetylated nonhistone proteins, 
which alter gene expression as mentioned earlier. It thus has 
a broad spectrum of epigenetic activities and, consequently, 
diverse effects on cancer cells. Vorinostat induces apoptosis 
by upregulating proapoptotic proteins and downregulating 
the expression of antiapoptotic molecules, including the 
intracellular inhibitors of apoptosis FLIP and survivin.56,57 
It decreases the expression of cyclin D1 by inhibiting 
its translation through affecting activity of PI3K and its 
downstream proteins.58 It has also been shown to decrease 
the expression of CDK4 along with that of cyclin D1.59 
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Furthermore,   vorinostat induces expression of p21 through 
histone acetylation, inhibiting the function of the cyclin 
D/CDK4 complex.60,61 Thus vorinostat affects the cell-cycle 
by suppressing the expression and function of cell cycle-
  associated proteins. Inhibition of angiogenesis is another 
aspect of its action. Vorinostat reportedly inhibits angiogen-
esis by decreasing the expression of the vascular endothelial 
growth factor (VEGF) receptor and inhibits VEGF-induced 
angiogenesis.62 Vorinostat inhibits HDAC6 and this may 
be another important mechanism of action. Ablation of 
HDAC6 has been shown to induce hyperacetylation of 
heat shock protein 90, thereby abrogating its ATP binding 
activity and disrupting its chaperone function and resulting 
in polyubiquitination.63,64 This mechanism theoretically sup-
ports the use of vorinostat in combination with proteasome 
inhibitors, which is discussed later in this review.
Efficacy of vorinostat  
as a single agent
The results of clinical trials investigating the efficacy of 
vorinostat as a single agent are summarized in Table 1. The 
following sections review the results of selected clinical trials 
in patients with CTCL, other hematological malignancies, 
or solid tumors.
Primary CTCL
CTCL comprises a heterogeneous group of lymphoprolif-
erative disorders characterized by skin lesions composed 
of malignant clonal T lymphocytes.65 Mycosis fungoides, 
Sézary syndrome, and other cutaneous T-cell lymphomas 
arising in the skin are parts of a broader spectrum of 
CTCL.66 Numerous therapeutic options are available, both 
local (corticosteroids, nitrogen mustard, carmustine, topical 
retinoids, rexinoid, ultraviolet light therapy, and irradiation) 
and systemic (bexarotene and denileukin diftitox), but none 
has been shown to be curative.67 Vorinostat was approved 
by the Food and Drug Administration in October 2006 for 
the treatment of advanced primary CTCL.21 According to a 
Phase I clinical trial recruiting 73 patients, for continuous 
daily dosing the maximum tolerated dose was 400 mg once 
daily or 200 mg twice daily, and for three consecutive days 
per week dosing it was 300 mg twice daily; the major dose-
limiting toxicities were anorexia, dehydration, diarrhea, and 
fatigue.68 According to a Phase I study in Japanese patients 
with solid tumors, doses of 200 mg twice daily or 500 mg 
once daily for 14 days followed by a 7-day rest were well 
tolerated.69 In a Phase II trial enrolling 33 patients with 
refractory CTCL,70 patients were given either 400 mg daily,   
300 mg twice daily for 3 days with 4 days of rest, or 300 mg 
twice daily for 14 days with 7 days of rest followed by 200 mg 
twice daily. Eight patients achieved a partial response, seven 
with advanced disease and four with Sézary syndrome. The 
median time to response, duration of response, and time to 
progression were, respectively, 11.9, 15.1, and 12.1 weeks. 
Fourteen of the 31 evaluable patients had relief of pruritus. 
In another Phase II study71 enrolling 74 patients with stage 
IB-IVA mycosis fungoides/Sézary syndrome and treating 
them with 400 mg of oral vorinostat daily until disease pro-
gression or intolerable toxicity, the overall objective response 
rate was 29.7%, the median overall duration of response was 
more than 185 days, the median time to progression was 
4.9 months overall and more than 9.8 months for stage IIB 
or higher responders, and 32% of the patients had relief of 
pruritus. The most common adverse events were mild (below 
grade 2), ie, diarrhea (49%), fatigue (46%), nausea (43%), 
and anorexia (26%). Grade 3 or higher events were fatigue 
(5%), pulmonary embolism (5%), thrombocytopenia (5%), 
and nausea (4%). Vorinostat has thus been shown to be a 
safe, effective, and tolerable agent in the treatment of CTCL. 
In July 2011 the Japanese Ministry of Health, Labour, and 
Welfare approved vorinostat for the treatment of CTCL.
Other hematological malignances
In a Phase II trial, 37 patients with relapsed or untreated acute 
myeloid leukemia were treated with vorinostat at doses of 
either 400 mg daily or 200 mg three times daily for 14 days 
followed by one week of rest.72 One complete response was 
observed, with a duration of response of more than 398 days. 
The median time to progression was 42 days for the patients 
given 400 mg daily and 46 days for the patients given 200 mg 
three times daily. In another Phase II study,73 18 patients 
with relapsed diffuse large B cell lymphoma were recruited 
and given oral vorinostat 300 mg twice a day. Median time 
to progression was 44 days. One patient had a complete 
response with duration of response $468 days and one had 
stable disease (301 days). Grade 1 and 2 toxicities were 
diarrhea, fatigue, nausea, anemia, and vomiting.   Toxicities 
of grade 3 or higher were thrombocytopenia (16.7%) and 
asthenia (11.1%). A Phase I trial was conducted using oral 
vorinostat to treat patients with relapsed or refractory multiple 
  myeloma.74 Ten patients given 200, 250, or 300 mg twice 
daily 5 days a week for 4 weeks or 200, 300, or 400 mg 
twice daily for 14 days of a 21-day cycle were evaluable. 
There was one patient with a minimal response and nine 
with stable disease. Toxicities were mostly below grade 
2 and included fatigue, anorexia, dehydration, diarrhea, 
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and nausea. The efficacy of vorinostat was also evaluated 
in Japanese patients with malignant lymphoma (follicular 
lymphoma, mantle cell lymphoma, diffuse large B-cell 
lymphoma, and CTCL).75 Ten patients were enrolled in 
this study, and 100 mg or 200 mg was given twice daily for 
14 consecutive days followed by a 1-week rest. The objective 
response rate was 40% and there were three unconfirmed 
complete responses and one partial response. In a recent, 
larger Phase II trial of vorinostat in patients with relapsed 
or refractory indolent non-Hodgkin’s lymphoma and mantle 
cell   lymphoma, 35 patients given 200 mg twice daily on 
days 1–14 of a 21-day cycle showed an objective response 
rate of 29% including five complete responses and five par-
tial responses.76 Vorinostat is thus thought to have modest 
  activity against hematological malignancies.
Solid tumors
The efficacy of vorinostat has also been investigated in 
patients with solid tumors. In a Phase II trial in patients 
with recurrent and/or metastatic head and neck cancer,77 
12 patients were given oral vorinostat 400 mg once daily. 
Three patients had stable disease for periods ranging from 
9 to 26 weeks, but no confirmed partial response or complete 
response was observed. Drug-related toxicities of grades 
3 or 4 were thrombocytopenia (n = 3), anorexia (n = 2), and 
dehydration (n = 2). In another Phase II trial in patients with 
recurrent or persistent epithelial ovarian or primary peritoneal 
carcinoma,78 27 patients were enrolled and given a 400 mg 
daily oral dose of vorinostat until disease progression or unac-
ceptable toxicity. Two patients survived progression-free for 
over 6 months and one partial response was observed. The 
grade 4 toxicities were leucopenia (one patient) and neutro-
penia (one patient). Grade 3 toxicities were constitutional 
(11%), gastrointestinal (11%), neutropenia, metabolic abnor-
malities, thrombocytopenia (7%), neurologic complaints, and 
pain (4%). The efficacy of vorinostat was also investigated 
in 16 patients with relapsed or refractory breast cancer, 
nonsmall cell lung cancer, or colorectal cancer.79 The patients 
were given 200, 300, or 400 mg by mouth twice daily for 
14 days followed by a 7-day rest until disease progression 
or intolerable toxicity. Eight patients had stable disease, 
but there were no confirmed responses. The median time to 
progression was 33.5 days. The most common drug-related 
adverse events were anorexia (81%), fatigue (62%), nausea 
(62%), diarrhea (56%), vomiting (56%), thrombocytopenia 
(50%), and weight loss (50%). Grade 4 toxicities included 
thrombocytopenia (50%), anemia (12%), asthenia (12%), and 
nausea (12%). The most recent trial80 enrolled 27 patients 
with metastatic hormone-refractory prostate cancer who 
were given 400 mg vorinostat by mouth daily. Median time 
to progression and overall survival were 2.8 and 11.7 months. 
The most common adverse events were fatigue (81%), nausea 
(74%), anorexia (59%), vomiting (33%), diarrhea (33%), 
and weight loss (26%). Other Phase II studies of the effec-
tiveness of vorinostat against solid tumors included patients 
with relapsed nonsmall cell lung cancer,81 glioblastoma,82 
and metastatic breast cancer,83 and rarely showed objective 
responses.
Combination therapies  
using vorinostat
Clinical trials revealed that vorinostat is a promising agent 
to treat CTCL and some other hematological   malignancies, 
but its efficacy against solid tumors is disappointing. 
  Combination therapies using vorinostat and other agents 
have therefore been investigated, and their results are sum-
marized in Table 2. The agent with which vorinostat was 
most often combined in clinical trials was 5-fluorouracil. The 
rationale for this is that vorinostat could overcome resistance 
to fluorouracil by downregulating thymidylate synthase, 
which is associated with resistance to fluorouracil.84 In one 
Phase I/II clinical trial in which vorinostat was combined 
with 5-fluorouracil and leucovorin to treat patients with 
metastatic colorectal cancer, two of 10 patients achieved 
significant disease stabilization for 4 and 6 months.85 Better 
results were obtained in another trial using the combination 
of vorinostat, 5-fluorouracil, and leucovorin.86 Twenty-one of 
38 patients with fluorouracil-refractory colorectal cancer had 
stable disease, and one had a partial response. The combina-
tion of vorinostat, 5-fluorouracil, leucovorin, and oxaliplatin 
was also investigated in a Phase I trial in colorectal cancer 
patients.87 Twenty-one patients were enrolled, but no patient 
developed an objective response. Stable disease was con-
firmed in five patients. Thus, the efficacy of the combination 
of vorinostat and 5-fluorouracil seems to be limited.
The combination of vorinostat, carboplatin, and paclitaxel 
was studied in two clinical trials. Enhancement of cisplatin 
activity by increased platinum adduct formation of the more 
open DNA configuration induced by HDAC inhibition88 and 
enhancement of taxane activity by alterations in α-tubulin 
acetylation that are due to the inhibition of HDAC689 are 
thought to be the mechanisms by which the combination acts. 
In a Phase I trial, 28 patients with advanced solid malignan-
cies were treated with this combination therapy.90 The results 
were encouraging. In the 25 patients evaluable for response, 
stable disease occurred in seven patients and partial responses 
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occurred in 10 patients with nonsmall cell lung cancer and 
one with head and neck cancer. Given the results of this trial, 
a Phase II clinical trial of the combination was conducted.91 
Patients with previously untreated stage IIIB or IV nonsmall 
cell lung cancer were treated with carboplatin and paclitaxel 
combined with either vorinostat or a placebo. In 94 evaluable 
patients, the confirmed response rate was 34% with vorinos-
tat and 12.5% with placebo. One patient in the vorinostat 
arm had a complete response. A favorable trend toward 
improvement in median progression-free survival (6.0 months 
  versus 4.1 months) and overall survival (13.0 months versus 
9.7 months) was also observed in the vorinostat arm. The one-
year overall survival rates were 51% for the vorinostat-treated 
group and 33% for the placebo-treated group. These studies 
provide a rationale for combining vorinostat, carboplatin, and 
paclitaxel and assessing the efficacy of the combination in 
other malignancies treated with carboplatin and paclitaxel.
Inducing endoplasmic reticulum stress and protein 
  ubiquitination has recently emerged as a novel approach to 
the treatment of malignancies.92 The combination of vorinostat 
and bortezomib, a proteasome inhibitor, induces endoplasmic 
reticulum stress. Vorinostat inhibits HDAC6, and inhibition 
of HDAC6 has been shown to induce hyperacetylation of 
heat shock protein 90, thereby abrogating its ATP-binding 
activity and disrupting its chaperone function.63,64 Combining 
vorinostat with bortezomib therefore enhances endoplasmic 
reticulum stress and accumulation of ubiquitinated proteins. 
This combination has also been shown not only to cause 
accumulation of ubiquitinated proteins, but also to enhance 
histone acetylation synergistically.93 Because the combination 
affects protein ubiquitination and histone acetylation, which 
are universal mechanisms of protein homeostasis and control 
of gene transcription, the molecular consequences of the com-
bination are diverse. The combination reportedly inhibits the 
RK and Akt pathways,94 diminishes expression of Bcr/Abl 
and cyclin D1, cleavage of p21CIP1, and phosphorylation of 
the retinoblastoma protein,95 and induces apoptosis.94–97 The 
result of a Phase I trial using this combination is   promising.98 
Twenty-three patients with relapsed and/or refractory mul-
tiple myeloma were enrolled in the study. The objective 
response rate was 42%, including three partial responses 
among nine patients who were refractory to bortezomib. The 
median time to progression was 4 months. Because of its 
unique mechanism of action, the combination of vorinostat 
and bortezomib may be a novel approach to the treatment of 
malignancies. Clinical trials using this combination against 
other types of cancer are expected.
It has been reported that HDACs are involved in the 
regulation of steroid hormone receptor-mediated cell sig-
naling and that inhibition of HDACs impairs the develop-
ment of tamoxifen resistance.99 In breast cancer patients 
resistant to hormone therapy, the combination of vorinostat 
Table 2 Results of clinical trials testing vorinostat in combination with other anticancer agents in various types of cancer
Trail Disease No of evaluable  
patients
Combined drug(s) Results
Phase i/ii (wilson PM, et al85) Metastatic colorectal cancer 10 5-FU/LV SD = 20%
Phase i (Fakih MG, et al86) FU-refractory colorectal cancer 38 5-FU/LV PR = 2.6%; SD = 55.3%
Phase i (Fakih MG, et al87) Refractory metastatic colorectal  
cancer
21 5-FU/LV and oxaliplatin SD = 23.8%
Phase i  
(Ramalingam SS, et al90)
NSCLC, head and neck cancer,  
bladder cancer, mesothelioma,  
and others
25 Carboplatin and paclitaxel PR = 44%; SD = 28%
Phase ii  
(Ramalingam SS, et al91)
Stage iiiB or iV NSCLC 94 Carboplatin and paclitaxel Confirmed response  
rate = 34% vs 12.5%;  
PFS = 6.0 mos vs 4.1 mos;  
OS = 13 mos vs 9.7 mos 
(vorinostat vs placebo)
Phase i (Badros A, et al98) Relapsed and/or refractory  
multiple myeloma
23 Bortezomib PR = 42%; TTP = 4 mos
Phase ii  
(Munster PN, et al100)
Refractory breast cancer 43 Tamoxifen ORR = 19%; clinical benefit 
rate (response or stable 
disease .24 weeks) = 40%; 
DOR = 10.3 mos
Phase i  
(Stathis A, et al102)
Advanced solid tumors or  
non-Hodgkin’s lymphomas
38 Decitabine SD = 29%
Abbreviations: 5-FU, 5-fluorouracil; DOR, median duration of response; LV, leucovorin; NSCLC, nonsmall cell lung cancer; ORR, objective response rate; PFS, median 
progression-free survival; PR, partial response; SD, stable disease; TTP, median time to progression.
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and tamoxifen was investigated with encouraging results. 
In 43 patients treated, an objective response rate of 19%, 
a clinical benefit rate of 40%, and a median duration of 
response of 10.3 months were observed.100
Combining decitabine, a demethylating agent, and 
  vorinostat was shown to result in the re-expression of tumor 
suppressor genes.101 When the combination of vorinostat and 
decitabine was examined in patients with advanced solid 
tumors or non-Hodgkin lymphoma, 29% of treated patients 
showed stable disease.102
Thus, some combination therapies using vorinostat have 
promising anticancer activity. Further clinical trials with 
these combinations and with combinations of vorinostat 
and other anticancer agents with other mechanisms of action 
are required in order to establish novel effective treatment 
strategies against advanced malignancies.
Summary
Vorinostat, a histone deacetylase inhibitor, is a novel promis-
ing anticancer agent approved in Japan in July 2011 for the 
treatment of CTCL. Because it affects the principal mecha-
nisms of gene expression by causing acetylated histones and 
acetylated nonhistone proteins to accumulate rather than 
by merely inhibiting specific signal transduction pathways, 
as many currently used anticancer agents do, its effects are 
diverse and potentially effective in many types of malignancies 
that are refractory to currently available treatment modalities. 
Although the efficacy of vorinostat alone in patients with 
advanced solid tumor is unfortunately limited, some recent 
studies have reported a favorable response to vorinostat 
in combination with other anticancer agents. Future basic 
research and clinical trials of vorinostat should focus on more 
effective combinations of vorinostat with other drugs.
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